Table 1.
Patient demographics and disease characteristics
| Schedule Aa (n = 63) | Schedule Ba (n = 58) | Total (N = 121) | |
|---|---|---|---|
| Median age, y (range) | 60 (23–76) | 53 (32–79) | 58 (23–79) |
| Gender, n (%) | |||
| Male | 29 (46.0) | 28 (48.3) | 57 (47.1) |
| Female | 34 (54.0) | 30 (51.7) | 64 (52.9) |
| Baseline ECOG PS, n (%) | |||
| 0 | 28 (44.4) | 24 (41.4) | 52 (43.0) |
| 1 | 32 (50.8) | 32 (55.2) | 64 (52.9) |
| 2 | 3 (4.8) | 2 (3.4) | 5 (4.1) |
| Type of cancer, n (%) | |||
| Colorectal | 7 (11.1) | 23 (39.7) | 30 (24.8) |
| Skin | 6 (9.5) | 10 (17.2) | 16 (13.2) |
| Pancreas | 6 (9.5) | 5 (8.6) | 11 (9.1) |
| Sarcoma | 6 (9.5) | 2 (3.4) | 8 (6.6) |
| Breast | 3 (4.8) | 2 (3.4) | 5 (4.1) |
| Prostate | 4 (6.3) | 0 (0) | 4 (3.3) |
| Thyroid/parathyroid | 4 (6.3) | 0 (0) | 4 (3.3) |
| Non-small cell carcinoma | 3 (4.8) | 1 (1.7) | 4 (3.3) |
| Liver and biliary tree | 2 (3.2) | 2 (3.4) | 4 (3.3) |
| Ovary and fallopian tube | 2 (3.2) | 2 (3.4) | 4 (3.3) |
| Otherb | 20 (31.7) | 11 (19.0) | 31 (25.6)b |
| Prior anticancer therapy, n (%) | |||
| Chemotherapy | 58 (92.1) | 54 (93.1) | 112 (92.6) |
| 1–3 | 31 (49.2) | 24 (41.4) | 55 (45.5) |
| 4–6 | 19 (30.2) | 22 (37.9) | 41 (33.9) |
| >7 | 8 (12.7) | 8 (13.8) | 16 (13.2) |
| Surgery | 55 (87.3) | 55 (94.8) | 110 (90.9) |
| Radiotherapy | 35 (55.6) | 24 (41.4) | 59 (48.8) |
ECOG PS Eastern Cooperative Oncology Group performance status
aSchedule A: Days 1 and 15 of a 4-week cycle; schedule B: Day 1 of a 3-week cycle
bIncludes head and neck (n = 3), esophagus (n = 3), stomach (n = 2), cervix/vagina/vulva (n = 3), gastrointestinal tract (n = 3), other endocrine cancer (n = 2), pleura (n = 2), lymphoma/leukemia (n = 1), small intestine (n = 1), lung (n = 1), anal region (n = 1), bladder (n = 1), urethra/penis (n = 1), small cell carcinoma (n = 1), mediastinum (n = 1), uterus (n = 1), adrenal (n = 1), and unknown (n = 3)